Danaher Appoints Former Medtronic VP Yu Jing as President of China Diagnostics Platform Following Chen Xiaosui's Departure
Medtronic
Medical Device Manufacturer
At the beginning of 2026, the health industry ushered in a new round of executive changes.
January 13,Danaher CorporationIt is officially announced that Chen Xiaosui (Rosa), President of China Diagnostics Platform, will soon leave Danaher China to embark on a new professional journey.
At the same time,OriginalMedtronicVice President, General Manager of China Orthopedics and Neurosurgery BusinessYu Jing will join, taking overPresident of Danaher China Diagnostic Platform.
As a leading figure who has深耕ed in the 大健康 field for over two decades, Chen Xiaosui's new professional journey not only marks a significant leap in their personal career but also reflects that 长期主义 remains a crucial anchor point in the ongoing transformation of China's 大健康 industry.
Chen Xiaosui's four and a half years at Danaher coincided with a critical cycle of密集 policy adjustments and intensifying market competition in China's in vitro diagnostics (IVD) industry.
Chen Xiaosui
In September 2021, Chen Xiaosui joined Danaher, taking on the role for the group's medical diagnostics division.DBSThe heavy responsibility of the business system. In less than three years thereafter, she achieved two promotions.
February 2022,She was promoted to Vice President and General Manager of Beckman Coulter Diagnostics China, leading the commercial team; in January 2023, her responsibilities expanded further to support Dx manufacturing, Dx-County, digitalization, and key account management functions.
January 2024,She was promoted to President of Danaher China Diagnostic Platform, overseeing the diagnostic businesses of Beckman Coulter, Radiometer, Leica, and others, becoming a core member of Danaher’s leadership team in China.
Chen Xiaosui's promotion timeline also reflects Danaher's recognition of her ability to execute the company's localization strategy in the Chinese market.
Danaher stated in the email that Chen Xiaosui has made significant and lasting contributions to Beckman Coulter Diagnostics China and the Danaher China Diagnostics Platform.
Under her leadership, the team successfully navigated the constantly evolving and complex IVD landscape through centralized procurement (VBP) Improved commercial performance and gained more market share, while strengthening operational capabilities in China.
Chen Xiaosui encourages collaboration between diagnostic business companies, helping to unify goals and generate greater impact in China's rapidly developing and dynamic healthcare sector.
She led her team in advancing localization and open innovation, making Danaher Diagnostics' product portfolio more aligned with market demands, improving accessibility, and continuously enhancing standards in quality, compliance, and customer experience.
Her commitment to DBS excellence has enhanced the group's capabilities, accelerated decision-making, and supported outstanding performance.
At the same time, Danaher stated in the email,Yu JingWith extensive industry leadership and business operations experience. Through these roles, she has established a solid foundation in local operations and customer collaboration.
Recently, the frequent changes in senior executives of foreign companies in China's healthcare industry may reflect the new market logic in the next phase; however, long-termism still applies.
In recent years, China's health market has faced enormous challenges.Under the changing situation,In 2022, Danaher proposed "Launching China"Strategy.
Under the leadership of Peng Yang, Danaher Global Vice President and China Group President,At the 2023 CIIE, Danaher proposed again"China Innovation" Local Strategy 2.0, proposing a dual innovation acceleration engine for clinical-industry integration, to build a localized medical ecosystem.
Under the "Create and Elevate China" strategy,Chen Xiaosui becomesFirmPromoters and Implementers.
Accelerate the localization and implementation of the four operating companies, mainly Beckman, in China.Beckman Coulter Becomes the First Foreign IVD Company to Complete Full Hardware Localization, Including High-End Automation Lines, in China, the localization of reagents in China is accelerating simultaneously;More than 80% of the platform's diagnostic instruments and equipment are produced locally in China.Completed a total of 17 locally developed and collaborative innovation projects in China.。
Promote the diagnostic platform to complete multiple investment collaborations with local enterprises in China, integrate external innovative resources to improve product solutions, and better meet the needs of the Chinese market.
Complete the organizational transformation in the VBP era,And around efficiency and agility, adjust the personnel and management structure to build a strong execution, united and resilient, and agile response organizational talent team.
Most importantly, proactive adaptation under intensive policy changes.In response to industry challenges such as multiple rounds of volume-based procurement, Chen Xiaosui led the team in establishing a comprehensive response mechanism, relying on a deep understanding of industry policies and precise control of business logic.Beckman Coulter achieves counter-trend growth; not onlyBecoming the only one of the "Big Four" to protect and expand its market share in multiple rounds of biochemical and immunoassay centralized procurement, and emerging as a winner in the largest-ever tumor marker and thyroid function assay centralized procurement led by Anhui.。
Currently, China's large health market is transitioning fromZero-Sum Game, shifting towards a diversified new ecosystem of "technological complementarity, market integration, and win-win cooperation." Industry-leading talents with a combination of "global vision + local implementation capabilities" and understanding the logic of "medical devices + high-value consumables" may become the key link in connecting Chinese and foreign companies and stimulating innovation momentum.
It is reported that Chen Xiaosui will soon join another leading foreign medical device company in the industry. From Johnson & Johnson Medical, Philips, to Danaher, and onto the next journey, her long-term vision and leadership are believed to continue injecting certainty and growth momentum into the healthcare industry.